非小细胞肺腺癌驱动突变的研究进展

Research progress of driver mutations in non-small cell lung adenocarcinoma

随着主要肿瘤基因测序项目的开展,来源于体细胞突变的驱动突变以其在癌症发生、发展、治疗中的重要作用受到广泛关注.新驱动突变的不断确认使人们对非小细胞肺癌（NSCLC）的认识从传统的病理分类到现今的基于分子水平改变的分子分型;NSCLC患者也已不再被看做是同一类型肿瘤的集合,而是多种具有不同分子生物学行为、对不同的靶向药物敏感的患者群体.文章着重就NSCLC中腺癌这一特殊病理类型的常见驱动突变及相关转化性医学研究进展作一概述.

With the development of the main tumor gene sequencing projects,driver mutations have been put into the highlight due to its significant meaning on the cancer occurrence,development as well as treatment.In the past decade,based on the finding of new driver mutations,the knowledge of non-small cell lung cancer （NSCLC） have been improved from the traditional pathological classification to the current molecular classification.Meanwhile,NSCLC patients are no longer looked as an assembly of the same type tumor but various individuals with different molecular biology behavior with the different sensitivity to the targeted drugs.This article focuses on the recent discovery advances of driver mutations in lung adenocarcinoma.